Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the therapy for transthyretin amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback